This Week in Cell

An international team led by investigators in France describes a form of inborn error of innate immunity that could be reversed with antibodies targeting an immuno-stimulant produced by staph bacteria. The researchers did exome and targeted sequencing on a staph infection-prone child from a consanguineous family, narrowing in a mutation in TIRAP — a gene coding for a toll-like receptor (TLR) gene adaptor.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.